Incidence and therapy of relapse after allogenic hematopoietic stem cell transplantation

Introduction/Aim: Disease relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is one of the most common and severe post complications represents leading cause treatment failure patient death. The aim this study to assess frequency types relapse, in relation time occurrence; analyze influence conditioning regimens on review therapeutic options occurrence relapse; prognosis patients with relapse. Methods: This retrospective cohort included 58 who underwent (allo-HSCT). Pre-transplantation therapy was performed a reduced-intensity regimen (RIC) or myeloablative (MAC). diagnosis made through myelogram analysis, analysis cytogenetics, minimal residual disease (MRD), cellular chimerism, immunohematological chimerism blood group antigens. A database formed examined characteristics. Patient survival analyzed using Kaplan-Meier method log-rang test. Results: MAC (43 patients) used more frequently than RIC (15 patients), as regimen. After transplantation, 18 (34%) out 53 had choice did not affect but lived longer (38.5 ± 7 months) compared (27.8 3.5 months). However, difference without statistical significance (p = 0.318). median relapsed 26 5 months, while 41 4 months. Conclusion: Patients received time, an increase rate. In future, consideration should be given inclusion older 60 years, candidates for well possible use prophylactic aimed at preventing high-risk patients.